JPT History at a Glance
From its headquarters and production sites in Berlin, JPT Peptide Technologies GmbH has grown into a global peptide technology partner, delivering innovative peptide-based services, catalog products and kits, and supporting research and development in immunology, proteomics, drug discovery, vaccine development, and immunotherapies.
Along this journey, JPT has developed a series of pioneering peptide technologies that have shaped the company’s growth and reputation for innovation. These include:
PepMix™ Peptide Pools, an innovative solution designed to replace full-length proteins in T-cell stimulation and now widely regarded as a gold standard;
SpikeTides™, a unique range of isotope-labeled peptide specifications for proteomics assays;
PepStar™ Peptide Microarrays, an on-chip immobilized peptide platform for decoding protein interactions;
PepTrack™ Peptide Libraries, a high-throughput peptide production solution enabling the manufacture of one million peptides per year.
The following milestones mark important steps in JPT’s growth and evolution over time:
JPT is established in Berlin
JPT Peptide Technologies GmbH was founded as a spin-off of Jerini AG, a Berlin-based peptide drug discovery company. The name JPT stands for Jerini Peptide Technologies, and the company received its first ISO 9001 certification also in 2004.
Part of BioNTech and expanding R&D partnerships
JPT became a wholly owned subsidiary of BioNTech AG and expanded R&D partnerships in seromarker discovery, immune monitoring, diagnostics, vaccine target discovery, proteomics, and enzyme profiling.
Online access to peptide technologies
JPT launched an online shop, making catalog peptide microarrays, peptide pools, and intelligent peptide collections easier to access.
Participation in Human Proteome Project
JPT participated in the European Community-funded Human Proteome Project, a major international research initiative aimed at decoding the human proteome and advancing proteomics technologies through collaboration between academic and industrial partners.
Portfolio for immunotherapies and vaccines
JPT completed its product and service portfolio for every phase of immunotherapy and vaccine development, from target and epitope discovery through clinical application. With the development of Clinical Grade Peptides, JPT enabled peptide use in a wide range of clinical procedures, including autologous T-cell therapies.
ISO 9001:2015 certification
JPT was the first German biotech company to be certified according to the new standard DIN ISO 9001:2015, reinforcing quality management standards across peptide technologies and services.
Supporting COVID-19 vaccine research
JPT PepMixes™ and clinical grade peptides were successfully applied in the development of several leading COVID-19 vaccines.
New website, new team members, new lab space
JPT products contributed to SARS-CoV-2 vaccine development and more than 100 publications. JPT also launched a new website, hired new employees, and added more lab space.
20 years of peptide innovation
JPT celebrated its 20th anniversary in Berlin, welcomed new CEO Aurélien Claeyssen, hosted international ELISpot workshops, visited more than 300 labs in the US, received CIR certification for France, anded adds more new products to the peptide catalog.
A new home and a fresh brand era
JPT moved into the state-of-the-art House of Peptides, unveiled a refreshed logo and brand design, expanded its team and catalog, launched 1001 antigen peptides and Premium Grade PepMix™ Peptide Pools, and reached around 200 peptide-related publications in the year.
Today: enabling peptide research worldwide
With a team of more than 100 employees, millions of peptides produced, and customers in over 100 countries, JPT continues to deliver precise, reliable peptide solutions for preclinical and clinical research.
Future: advancing the next era of peptide innovation
Building on its scientific expertise, expanding product portfolio, and new House of Peptides, JPT is shaping the future of peptide-based research with new technologies, stronger collaborations, and continued support for immunology, proteomics, and therapeutic discovery.